Français
Deutsch
Español
Italiano
Português
日本語
한국어
Русский
Sports on TV for Sunday, August 27
Aug 27, 2023Philadelphia Phillies and St. Louis Cardinals play in game 2 of series
Aug 29, 2023Washington Nationals pitcher Stephen Strasburg, the 2019 World Series MVP, has decided to retire, an AP source says
Aug 22, 2023Lancaster County Challenger team ready to take Little League World Series stage
Aug 31, 2023Blue Jays host the Guardians to start 3
Aug 15, 2023Concord Biotech: US a key market, have strong presence in it: Ankur Vaid, Concord Biotech
Feb 26, 2024Read Stock Insights by ET for a quick analysis
Don’t miss out on ET Prime stories! Get your daily dose of business updates on WhatsApp. click here!
Reliance Industries Ltd (RIL) chairman Mukesh Ambani said his three children — daughter Isha and sons Akash and Anant — will be inducted on the board as non-executive directors. He will continue as chairman and managing director for another five years, he announced at the RIL annual general meeting (AGM) on Monday.
A trading platform dedicated to small and medium enterprises (SMEs) is currently witnessing a flood of public offerings on surging demand from rich individual domestic investors with the risk appetite for such small issuances.
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Now that your listing is done, let us talk about numbers and tell us what the company sees by way of revenue as well as PAT growing for FY24 and even beyond?Your EBITDA margin are at 40% and return on capital, ROE and ROC are in the range of 19 to 20%. So do you see a marked improvement even in your return ratios because if you are looking at adding capacity, operating leverage benefits would kick in?The entire pharma supply chain is a very complex supply chain, and there are wheels within wheels, but you are in a sense right at the entrance, which is that you give base fermentation products which are required for the pharmaceutical industry. So are you also exposed to the volatility within the pharma sector in terms of pricing or yours is more like a B2B product, it is going to be constant and will go irrespective of the big large trend?When you look ahead besides the top five products in your portfolio, tell me the newer therapies that you are looking at venturing into. I mean, would you for instance enter hormones or the steroids category?Why have you stayed away from the US markets in a very large manner because if I look at the list of countries where you are present Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and then US. Is my understanding right that you consciously stayed away from US market and you are going there now?Walk us through about the government and the institutional business side of yours, that is also a very large business and since you have a very formidable presence of 1500-1600 associations, what is happening there, what is the uniqueness of this business?You have very famous investors in your company and Rare Enterprises, very famous investors have invested in your company. Have any of the key investors who invested in your company a decade ago, 10 years ago, have they taken exit in the IPO?Your historical growth rate is 18% and after the capacity addition we expect it to grow higher than the historical growth rate. What will be that higher historical growth rate both in terms of margins and also in terms of CAGR top line?